Witzig TE - Search Results

1

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.

Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Kumar SK, et al. Among authors: witzig te. Blood. 2016 Nov 17;128(20):2415-2422. doi: 10.1182/blood-2016-05-717769. Epub 2016 Oct 4. Blood. 2016. PMID: 27702799 Free PMC article. Clinical Trial.

2

Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.

Garton JP, Gertz MA, Witzig TE, Greipp PR, Lust JA, Schroeder G, Kyle RA. Garton JP, et al. Among authors: witzig te. Arch Intern Med. 1995 Oct 23;155(19):2069-74. Arch Intern Med. 1995. PMID: 7575066 Clinical Trial.

3

Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma.

Witzig TE, Gertz MA, Pineda AA, Kyle RA, Greipp PR. Witzig TE, et al. Br J Haematol. 1995 Mar;89(3):640-2. doi: 10.1111/j.1365-2141.1995.tb08378.x. Br J Haematol. 1995. PMID: 7734368

4

Refractory and relapsing multiple myeloma treated by blood stem cell transplantation.

Gertz MA, Pineda AA, Chen MG, Letendre L, Greipp PR, Solberg LA Jr, Witzig TE, Garton JP, Inwards DJ, Litzow MR, et al. Gertz MA, et al. Among authors: witzig te. Am J Med Sci. 1995 Mar;309(3):152-61. doi: 10.1097/00000441-199503000-00006. Am J Med Sci. 1995. PMID: 7879820

5

Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma.

Tefferi A, Witzig TE, Reid JM, Li CY, Ames MM. Tefferi A, et al. Among authors: witzig te. J Clin Oncol. 1994 Mar;12(3):569-74. doi: 10.1200/JCO.1994.12.3.569. J Clin Oncol. 1994. PMID: 8120555 Clinical Trial.

6

Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.

Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Greipp PR, et al. Among authors: witzig te. Blood. 1993 Jun 15;81(12):3382-7. Blood. 1993. PMID: 8507875 Free article.

7

Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: when is the optimal time for stem cell harvest?

Witzig TE, Gertz MA, Lust JA, Kyle RA, Greipp PR. Witzig TE, et al. Leuk Lymphoma. 1995 Nov;19(5-6):417-22. doi: 10.3109/10428199509112199. Leuk Lymphoma. 1995. PMID: 8590841

8

A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma.

Gertz MA, Garton JP, Greipp PR, Witzig TE, Kyle RA. Gertz MA, et al. Among authors: witzig te. Leukemia. 1995 Dec;9(12):2115-8. Leukemia. 1995. PMID: 8609725 Clinical Trial.

9

Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma.

Witzig TE, Gertz MA, Lust JA, Kyle RA, O'Fallon WM, Greipp PR. Witzig TE, et al. Blood. 1996 Sep 1;88(5):1780-7. Blood. 1996. PMID: 8781435 Free article.

10

Biology and treatment of myeloma.

Greipp PR, Witzig T. Greipp PR, et al. Curr Opin Oncol. 1996 Jan;8(1):20-7. doi: 10.1097/00001622-199601000-00004. Curr Opin Oncol. 1996. PMID: 8868095 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

629 results

Search Page